GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Modus Therapeutics Holding AB (FRA:99Z) » Definitions » Other Income (Expense)

Modus Therapeutics Holding AB (FRA:99Z) Other Income (Expense) : €0.00 Mil (TTM As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Modus Therapeutics Holding AB Other Income (Expense)?

Modus Therapeutics Holding AB's other income expense for the Modus Therapeutics Holding AB's pretax income for the three months ended in Sep. 2024 was €0.00 Mil. Its other income expense for the trailing twelve months (TTM) ended in Sep. 2024 was €0.00 Mil.

Modus Therapeutics Holding AB Other Income (Expense) Historical Data

The historical data trend for Modus Therapeutics Holding AB's Other Income (Expense) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Modus Therapeutics Holding AB Other Income (Expense) Chart

Modus Therapeutics Holding AB Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Other Income (Expense)
- - - - -

Modus Therapeutics Holding AB Quarterly Data
Dec19 Mar20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Other Income (Expense) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Modus Therapeutics Holding AB Other Income (Expense) Calculation

Other income expense includes minority interest. Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company.

Other Income (Expense) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Modus Therapeutics Holding AB  (FRA:99Z) Other Income (Expense) Explanation

Minority interest is reported on the consolidated income statement as a share of profit belonging to minority shareholders.

Modus Therapeutics Holding AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Modus Therapeutics Holding AB (FRA:99Z) » Definitions » Other Income (Expense)
Comparable Companies
OSTO:ONCOZ OSTO:FLUI OSTO:CMOTEC B XSAT:DBP B OSTO:PILA OSTO:SPAGO XSAT:APTA XSAT:PHAL XSAT:CHOSA OSTO:2CUREX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
MODTX:Sweden
Address
Olof Palmes gata 29 IV, Stockholm, SWE, 111 22
Website
https://www.modustx.com
Modus Therapeutics Holding AB is a Swedish clinical biotechnology company developing a treatment for sepsis, endotoxemia, severe malaria, and other disorders with severe systemic inflammation as well as states of anemia, related to chronic inflammation such as kidney diseases through its patented polysaccharide sevuparin. The drug candidate sevuparin has the opportunity to benefit patients and save large healthcare costs.

Modus Therapeutics Holding AB Headlines

No Headlines